{
    "clinical_study": {
        "@rank": "87337", 
        "arm_group": [
            {
                "arm_group_label": "A01016", 
                "arm_group_type": "Experimental", 
                "description": "A01016 administered as a single intravitreal injection to the study eye at baseline"
            }, 
            {
                "arm_group_label": "Sham injection", 
                "arm_group_type": "Sham Comparator", 
                "description": "Single sham injection to the study eye at baseline"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the superiority of a single intravitreal injection\n      of A01016 compared to sham-injection in subjects with symptomatic vitreomacular adhesion\n      (VMA)."
        }, 
        "brief_title": "A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Vitreomacular Adhesion", 
        "condition_browse": {
            "mesh_term": "Tissue Adhesions"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptomatic vitreomacular adhesion (VMA) which, in the opinion of the Investigator,\n             is related to decreased visual function;\n\n          -  Best corrected visual acuity (BCVA) of 20/25 or worse in the study eye;\n\n          -  BCVA of 20/800 or better in the non-study eye;\n\n          -  Provide written informed consent;\n\n          -  Follow specified instructions during study period;\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Evidence of proliferative retinopathy, exudative age-related macular degeneration, or\n             retinal vein occlusion in the study eye;\n\n          -  Vitreous hemorrhage or other opacification;\n\n          -  High myopia in the study eye;\n\n          -  Ocular surgery, laser photocoagulation treatment, or intravitreal injection(s) in the\n             study eye in the prior 3 months;\n\n          -  Uncontrolled glaucoma in the study eye;\n\n          -  History of retinal detachment in either eye;\n\n          -  Active infection in either eye;\n\n          -  Pregnant or of child-bearing potential and not utilizing acceptable form of\n             contraception;\n\n          -  Participation in another investigational drug study within 30 days prior to this\n             study;\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "168", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01889251", 
            "org_study_id": "J-12-075"
        }, 
        "intervention": [
            {
                "arm_group_label": "A01016", 
                "intervention_name": "A01016", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sham injection", 
                "intervention_name": "Sham injection", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Vitreomacular Adhesion", 
            "Vitreomacular Traction", 
            "Vitreomacular Traction Syndrome", 
            "Vitrectomy", 
            "Central Visual Field Defect", 
            "Blind Spot", 
            "Intravitreal Injection", 
            "Macula", 
            "Retina", 
            "Decreased Visual Acuity", 
            "Visual Complaint", 
            "SD-OCT", 
            "Macular Hole"
        ], 
        "lastchanged_date": "March 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }, 
                "name": "Contact Alcon for Trial Locations"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Alcon Japan, Ltd.", 
            "last_name": "Atsushi Morishima", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "As determined by masked Central Reading Center (CRC) Spectral Domain Optical Coherence Tomography (SD-OCT)", 
            "measure": "Proportion of Subjects with Non-Surgical Resolution of Vitreomacular Adhesion", 
            "safety_issue": "No", 
            "time_frame": "Day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01889251"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}